{"id":49322,"date":"2013-06-29T07:36:02","date_gmt":"2013-06-29T07:36:02","guid":{"rendered":"https:\/\/mppt.hu\/project\/2013-junius-xv-evfolyam-2-szam\/"},"modified":"2020-10-29T15:34:40","modified_gmt":"2020-10-29T15:34:40","slug":"2013-junius-xv-evfolyam-2-szam","status":"publish","type":"project","link":"https:\/\/mppt.hu\/en\/project\/2013-junius-xv-evfolyam-2-szam\/","title":{"rendered":"Volume 15, Issue 2, June 2013"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;3.22.7&#8243; custom_padding=&#8221;||5px|||&#8221;][et_pb_row _builder_version=&#8221;3.25&#8243;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;3.27.4&#8243;]<\/p>\n<h4 style=\"text-align: center;\">VOLUME\u00a0 15, ISSUE 2, JUNE 2013<\/h4>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; specialty=&#8221;on&#8221; _builder_version=&#8221;3.22.3&#8243; custom_padding=&#8221;24px|0px|25px|0px|false|false&#8221;][et_pb_column type=&#8221;3_4&#8243; specialty_columns=&#8221;3&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_row_inner _builder_version=&#8221;3.25&#8243;][et_pb_column_inner saved_specialty_column_type=&#8221;3_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_blurb title=&#8221;Editoral in Hungarian &#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/szerklevel%20miklya.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/szerklevel miklya.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>Ildik\u00f3 Miklya<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;4.6.6&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<div class=\"artbody\">\n<p>A j\u00f6v\u0151 orvostudom\u00e1ny\u00e1nak egyik jelent\u0151s feladata a prevenci\u00f3s lehet\u0151s\u00e9gek kidolgoz\u00e1sa min\u00e9l t\u00f6bb medicin\u00e1lis \u00e1gazatban, mert ez a leghat\u00e9konyabb m\u00f3dszer az eg\u00e9szs\u00e9gmeg\u0151rz\u00e9s ter\u00fclet\u00e9n. M\u00e1r a Semmelweis Egyetem valamennyi kar\u00e1n is 2012-ben elindult a \u201ePrevenci\u00f3 az eg\u00e9szs\u00e9g\u00e9rt\u201d c\u00edm\u0171 2 f\u00e9l\u00e9ves tant\u00e1rgy oktat\u00e1sa, mely j\u00f3l mutatja, hogy mennyire fontos r\u00e9sze e ter\u00fclet az orvosl\u00e1snak. 2013-ban is folytat\u00f3dik \u201eMagyarorsz\u00e1g \u00e1tfog\u00f3 eg\u00e9szs\u00e9gv\u00e9delmi sz\u0171r\u0151programja 2010-2020\u201d, mely nagym\u00e9rt\u00e9kben el\u0151seg\u00edti az eg\u00e9szs\u00e9gv\u00e9delem t\u00f6bbdimenzi\u00f3s lehet\u0151s\u00e9geinek felismer\u00e9s\u00e9t. Napjainkban m\u00e1r sz\u00e1mos olyan prevenci\u00f3s lehet\u0151s\u00e9get ismer\u00fcnk, melyek seg\u00edts\u00e9g\u00e9vel elker\u00fclhet\u00fcnk s\u00falyos, \u00e9letvesz\u00e9lyes \u00e1llapotokat, kik\u00fcsz\u00f6b\u00f6lhet\u00fcnk eg\u00e9szs\u00e9get fenyeget\u0151 k\u00e1ros t\u00e9nyez\u0151ket, megv\u00e1ltoztathatjuk nem megfelel\u0151 \u00e9letm\u00f3dunkat, t\u00e1pl\u00e1lkoz\u00e1si szok\u00e1sainkat, melyek hozz\u00e1j\u00e1rulhatnak ahhoz, hogy szervezet\u00fcnk betegg\u00e9 v\u00e1ljon. &#8230;<\/p>\n<p>Miklya Ildik\u00f3<\/p>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;Association between mood characteristics and polymorphisms of glial cell line-derived neurotrophic factor (GNDF) in patients with depression&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/kotyuk.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/kotyuk.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>Eszter Kotyuk, N\u00f3ra N\u00e9meth, Zsuzsa Halmai, G\u00e1bor Faludi, M\u00e1ria\u00a0 Sasv\u00e1ri-Sz\u00e9kely and Anna Sz\u00e9kely<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;4.6.6&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<div class=\"artbody\">\n<p>Glial cell line-derived neurotrophic factor (GNDF) plays an important role in the development<br \/> and synaptic plasticity of dopaminergic neurons, thus it could be an important therapeutic<br \/> factor in Parkinson\u2019s disease. Results from candidate gene studies of GDNF in psychiatric disorders are contradictory. Moreover, the possible association between GDNF polymorphisms<br \/> and major- or bipolar depression has not been studied to date. Recently, our research group<br \/> has published an association between two GDNF polymorphisms (rs3812047, rs3096140) and<br \/> the individual variability of anxiety measured by the Hospital Anxiety and Depression Scale<br \/> (HADS) on a non-clinical sample. In the present study we further analyzed this association<br \/> on a sample with major- and bipolar depression: we used data from 183 MDD, 116 BP, and<br \/> 1172 control subjects and tested effect of GDNF rs3812047 and rs3096140 polymorphisms on<br \/> mood disorders. The case control design did not show significant differences in the genotype<br \/> distribution of BP or MDD versus control patients. However, in the bipolar group subjects with<br \/> rs3812047 A allele showed a significantly higher anxiety and depression mean score then<br \/> subjects with G allele (p=0.043). This result supports our previous findings demonstrated<br \/> on a non-clinical sample. Interestingly we found an opposite effect of the rs3812047 using<br \/> data from MDD patients: subjects with the G allele had higher depression scores (p=0.012).<br \/> An interaction effect of patient subgroups and genetic variants of the rs3812047 was observed<br \/> for both HADS subscales (anxiety: p=0.029; depression: 0.004). In summary, we confirmed the<br \/> previously published association between the rs3812047 A allele and mood characteristics<br \/> on the bipolar sample, and an effect in the opposite direction was detected in the patient<br \/> group with major depression. .<\/p>\n<p><em>(Neuropsychopharmacol Hung 2013; 15(2): 63-72)<\/em><\/p>\n<p>Keywords: glial cell line-derived neurotrophic factor (GNDF), rs3812047, rs3096140, bipolar depression, major depression, Hospital Anxiety and Depression Scale<\/p>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;Quality of life of patients with attention-deficit\/hyperactivity disorder: systematic review of the past 5 years&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/velo.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/velo.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>Szabina Vel\u0151, \u00c1gnes Kereszt\u00e9ny, D\u00f3ra\u00a0 Szentiv\u00e1nyi and Judit Bal\u00e1zs<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;4.6.6&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\">Aims: Attention-deficit\/hyperactivity disorder (ADHD) is one of the most prevalent childhood disorders which continues into adulthood in 30-60%. Many studies are interested in<br \/> the examination of the impact of ADHD on QoL. The aim of the current study is to provide<br \/> a systematic review of QoL studies in both children and adults with ADHD published in the<br \/> past five years focusing on three domains: 1. The impact of ADHD on QoL 2. The impact of<br \/> ADHD on QoL regarding age 3. The impact of ADHD on QoL regarding gender. Method:<br \/> A systematic literature search was conducted using the following databases: sciencedirect.com<br \/> and MEDLINE from 2008 to 2012. The following keywords were searched: quality of life, QoL,<br \/> attention deficit\/hyperactivity disorder, ADHD, gender differences, gender-related, age differences, age-related. We included studies into our review which investigated both adults and<br \/> children. Papers in English, German and Hungarian were included. Results: Fourteen relevant<br \/> articles were identified, among them 13 articles were in English, one in German and there<br \/> were no articles in Hungarian. All of the 14 articles confirmed the negative effects of ADHD<br \/> on QoL. Four studies dealt with the effects of ADHD on QoL regarding age: one paper claimed<br \/> that older people with ADHD have more impairments, but have better lefi-expectations than<br \/> younger people with ADHD, one study claimed that increasing age raises the odds of poor<br \/> QoL, while two studies did not find any changes on QoL of patients with ADHD regarding<br \/> age. Three studies dealt with the effect of ADHD on QoL regarding the gender: two studies<br \/> did not find difference on QoL of patients with ADHD, while one study found that women<br \/> with ADHD have lower QoL. Conclusions: Based on the studies published in the last 5 years,<br \/> patients with ADHD have lower QoL than healthy people; moreover, they have lower QoL<br \/> in many areas than patients with several somatic or other mental illnesses. More studies are<br \/> needed regarding the effects of ADHD on QoL by age and gender.<\/span><\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\"><\/span><\/p>\n<div class=\"artbody\">\n<p><em>(Neuropsychopharmacol Hung 2013; 15(2): 73-82)<\/em><\/p>\n<p>Keywords: systematic review, ADHD, quality of life, age, gender<\/p>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;Pharmacological treatment in alcohol-, drug- and benzodiazepine-dependent patients \u2013 the significance of trazodone&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/funk.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/funk.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>S\u00e1ndor Funk<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;4.6.6&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\">Currently detoxification of drug and alcohol dependent patients is pharmacologically<br \/> unresolved, and long-term treatment following the acute phase is also not very successful including a high number of relapses. We would need medications that on the short<br \/> term cease: the severe vegetative symptoms, the pain, the extremely distressing psychosyndrome characterised by restlessness, anxiety or acute depressive symptoms, and the craving.<br \/> The optimal would be if there was one medication capable of simultaneously alleviating or<br \/> diminishing all the above symptoms without causing dependency and preventing relapse<br \/> in the long-term. Dependency is almost all cases accompanied by primary and\/or secondary mood disorder or sleep disorder which should also be treated. It should be considered,<br \/> however, that following withdrawal of the agent benzodiazepine dependency often develops. The serotonin antagonist and reuptake inhibitor (SARI) trazodone is effective in the<br \/> treatment of depression accompanied by sleeping disorder and it has also shown efficacy<br \/> in alcohol and benzodiazepine-dependency. Its administration may improve the efficacy of<br \/> detoxification and treatment of following conditions, may decrease medication load and the<br \/> risk of the development of benzodiazepine dependency. In our clinical practice we frequently<br \/> use this agent to treat our patients simultaneously suffering from depression and addiction<br \/> problems, gaining experience comparing it to other pharmacotherapies (benzodiazepines<br \/> or other antidepressants). The medication is not approved for alcohol and drug dependence,<br \/> however, treatment t of comorbid conditions is not against to the official recommendations.<br \/> Our aim was, in addition to reviewing the literature, to share our experience which, although<br \/> cannot be considered an evidence based study, we deemed worthy of publishing. We cannot,<br \/> at this point, put forward a protocol addressing all related scientific problems and problems<br \/> of off-label treatment, and we could not so far treat enough patients with trazodone so that<br \/> our results would be statistically proven. \u201dAcute\u201d and long term treatment of dependency is<br \/> not sufficiently effective with a substantial relapse rate, which is in part related to the lack of<br \/> specific medication also for long term treatment. Among the available psychopharmacons,<br \/> trazodone is a possible choice, since, as based on patients\u2019 reports and clinical observations,<br \/> improvement of their depressive conditions and sleep problems potentially decreases the<br \/> risk of relapse of drug and alcohol dependence.<\/span><\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\"><\/span><\/p>\n<div class=\"artbody\">\n<p><em>(Neuropsychopharmacol Hung 2013; 15(2): 85-93)<\/em><\/p>\n<p>Keywords: depression, benzodiazepine-dependence, alcohol deoendence, drug-dependence, sleeping problems<\/p>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;Adult psychiatric aspects of Niemann-Pick Disease&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/faludi.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/faludi.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>G\u00e1bor Faludi, X\u00e9nia\u00a0 Gonda and P\u00e9ter D\u00f6me<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;4.6.6&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\">Niemann-Pick disease (NPD) is a group of distinct rare disorders (i.e. NPD-A; NPD-B;<br \/> NPD-C) \u2013 with autosomal recessive inheritance pattern &#8211; within the class of the inborn<br \/> disorders of the sphingolipid metabolism (called sphingolipidoses). Since patients<br \/> with NPD-A do not survive into adulthood and most patients with NPD-B are free<br \/> from neuropsychiatric symptoms we discuss only briefly type-A and -B NPD and<br \/> mainly constrict our review discussing the neuropsychiatric symptoms along with the<br \/> pathomechanism and the treatment of NPD-C. NPD-C is clinically heterogeneous, with<br \/> notable variations in age at onset, course and symptoms. Along with systemic signs,<br \/> neurologic and psychiatric symptoms are quite frequent in NPD-C and in its adult form<br \/> sometimes psychiatric symptoms are the first ones appearing. Unfortunately, the majority of clinicans (including adult psychiatrists and neurologists) are not aware of the<br \/> symptom group characteristic to NPD-C so patients with this disorder are frequently<br \/> misdiagnosed in the clinical practice. Since neuropsychiatric manifestations of NPD-C<br \/> may be treated with a substrate reduction agent (miglustat) with greater awareness<br \/> of the identification of neuropsychiatric symptoms in due course is the prerequisite<br \/> of proper and early diagnosis and treatment.<\/span><\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\"><\/span><\/p>\n<div class=\"artbody\">\n<p><em>(Neuropsychopharmacol Hung 2013; 15(2): 95-103)<\/em><\/p>\n<p>Keywords: Niemann-Pick disease type C, psychiatric symptoms, treatment, miglustat<\/p>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;Olanzapine pamoate injection \u2013 experience and case reports from clinical practice in Hungary&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/sumegi.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;4.6.6&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/sumegi.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>Andr\u00e1s S\u00fcmegi, J\u00e1nos\u00a0 K\u00e1lm\u00e1n and L\u00e1szl\u00f3 Csekey<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;4.6.6&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<p class=\"art\">When treating schizophrenia and other psychotic disorders, clinicians often encounter the<br \/>problems of non-adherence, which is almost the most common drawback of achieving remission and a better quality of life. The uncertain oral drug taking habits may lead to relapses and<br \/>rehospitalizations. Using second generation long acting injectables we have more possibilities<br \/>to avoid these problems. This review attempts to present and describe the pharmacological<br \/>background of the modern long acting injectables including patient cases where olanzapine<br \/>pamoate long acting injectable provided remission and better quality of life for the patients.<\/p>\n<p class=\"art\">\n<div class=\"artbody\">\n<p><em>(Neuropsychopharmacol Hung 2013; 15(2): 105-117)<\/em><\/p>\n<p>Keywords: olanzapine pamoate, long acting injectable, adherence<\/p>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;Psychiatric intensive care of Dementia praecox&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/gaszner.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xv-evfolyam-2-szam\/gaszner.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>Gabor Gaszner and Andrea Bartha<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;3.22.7&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<div class=\"artbody\">\n<p>33 year old British male\u2019s first presentation to mental health services was prompted by florid paranoid psychosis and volatile aggression. The patient developed agitated catatonia which eventually improved after 12 courses of ECT. The ongoing psychopharmacological management includes a second generation antipsychotic, a mood stabilizer antiepileptic and an anxiolytic. All investigations including blood tests, CSF analysis, urine and hair drug screen, CT and MRI scans with multidisciplinary medical consultations excluded any underlying pathology. The working diagnosis is an enduring paranoid psychosis with prominent signs of cognitive decline, all of which conclude to Kraepelin\u2019s Dementia Praecox.<\/p>\n<p><em>(Neuropsychopharmacol Hung 2013; 15(2): 118-121)<\/em><\/p>\n<p>Keywords: Paranoid psychosis, aggression, agitated catatonia, cognitive decline, dementia praecox<\/p>\n<\/div>\n<p>&nbsp;<\/p>\n<h4 class=\"art\">\u00a0<\/h4>\n<p>[\/et_pb_toggle][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/05\/cimlap-2013-junius-honlapra.jpg&#8221; align_tablet=&#8221;center&#8221; align_phone=&#8221;&#8221; align_last_edited=&#8221;on|desktop&#8221; _builder_version=&#8221;3.23&#8243; box_shadow_style=&#8221;preset3&#8243;][\/et_pb_image][\/et_pb_column][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>VOLUME\u00a0 15, ISSUE 2, JUNE 2013Ildik\u00f3 Miklya A j\u00f6v\u0151 orvostudom\u00e1ny\u00e1nak egyik jelent\u0151s feladata a prevenci\u00f3s lehet\u0151s\u00e9gek kidolgoz\u00e1sa min\u00e9l t\u00f6bb medicin\u00e1lis \u00e1gazatban, mert ez a leghat\u00e9konyabb m\u00f3dszer az eg\u00e9szs\u00e9gmeg\u0151rz\u00e9s ter\u00fclet\u00e9n. M\u00e1r a Semmelweis Egyetem valamennyi kar\u00e1n is 2012-ben elindult a \u201ePrevenci\u00f3 az eg\u00e9szs\u00e9g\u00e9rt\u201d c\u00edm\u0171 2 f\u00e9l\u00e9ves tant\u00e1rgy oktat\u00e1sa, mely j\u00f3l mutatja, hogy mennyire fontos r\u00e9sze e [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":48314,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[62],"project_tag":[],"class_list":["post-49322","project","type-project","status-publish","has-post-thumbnail","hentry","project_category-2013-en"],"_links":{"self":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/comments?post=49322"}],"version-history":[{"count":8,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49322\/revisions"}],"predecessor-version":[{"id":49686,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49322\/revisions\/49686"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media\/48314"}],"wp:attachment":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media?parent=49322"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_category?post=49322"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_tag?post=49322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}